Literature DB >> 21229614

Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.

Marios Politis1, Nicola Pavese, Yen F Tai, Lorenzo Kiferle, Sarah L Mason, David J Brooks, Sarah J Tabrizi, Roger A Barker, Paola Piccini.   

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder associated with motor, cognitive and psychiatric deficits. This study, using a multimodal imaging approach, aims to assess in vivo the functional and structural integrity of regions and regional networks linked with motor, cognitive and psychiatric function. Predicting disease onset in at risk individuals is problematic and thus we sought to investigate this by computing the 5-year probability of HD onset (p5 HD) and relating it to imaging parameters. Using MRI, (11)C-PK11195 and (11)C-raclopride PET, we have investigated volumes, levels of microglial activation and D2/D3 receptor binding in CAG repeat-matched groups of premanifest and symptomatic HD gene carriers. Findings were correlated with disease-burden and UHDRS scores. Atrophy was detected in sensorimotor striatum (SMST), substantia nigra, orbitofrontal and anterior prefrontal cortex in the premanifest HD. D2/D3 receptor binding was reduced and microglial activation increased in SMST and associative striatum (AST), bed nucleus of the stria terminalis, the amygdala and the hypothalamus. In symptomatic HD cases this extended to involve atrophy in globus pallidus, limbic striatum, the red nuclei, anterior cingulate cortex, and insula. D2/D3 receptor binding was additionally reduced in substantia nigra, globus pallidus, limbic striatum, anterior cingulate cortex and insula, and microglial activation increased in globus pallidus, limbic striatum and anterior prefrontal cortex. In premanifest HD, increased levels of microglial activation in the AST and in the regional network associated with cognitive function correlated with p5 HD onset. These data suggest that pathologically activated microglia in AST and other areas related to cognitive function, maybe better predictors of clinical onset and stresses the importance of early cognitive assessment in HD.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21229614      PMCID: PMC6870088          DOI: 10.1002/hbm.21008

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  37 in total

1.  D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain.

Authors:  Y L Hurd; M Suzuki; G C Sedvall
Journal:  J Chem Neuroanat       Date:  2001-07       Impact factor: 3.052

Review 2.  Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety.

Authors:  David L Walker; Donna J Toufexis; Michael Davis
Journal:  Eur J Pharmacol       Date:  2003-02-28       Impact factor: 4.432

Review 3.  Microglial functions and proteases.

Authors:  Hiroshi Nakanishi
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

4.  Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.

Authors:  Nicola Pavese; Thomasin C Andrews; David J Brooks; Aileen K Ho; Anne E Rosser; Roger A Barker; Trevor W Robbins; Barbara J Sahakian; Stephen B Dunnett; Paola Piccini
Journal:  Brain       Date:  2003-05       Impact factor: 13.501

Review 5.  Anterior prefrontal cortex: insights into function from anatomy and neuroimaging.

Authors:  Narender Ramnani; Adrian M Owen
Journal:  Nat Rev Neurosci       Date:  2004-03       Impact factor: 34.870

6.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition.

Authors:  H D Rosas; N D Hevelone; A K Zaleta; D N Greve; D H Salat; B Fischl
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

7.  CAG repeat number governs the development rate of pathology in Huntington's disease.

Authors:  J B Penney; J P Vonsattel; M E MacDonald; J F Gusella; R H Myers
Journal:  Ann Neurol       Date:  1997-05       Impact factor: 10.422

8.  Trinucleotide repeat length and progression of illness in Huntington's disease.

Authors:  K Kieburtz; M MacDonald; C Shih; A Feigin; K Steinberg; K Bordwell; C Zimmerman; J Srinidhi; J Sotack; J Gusella
Journal:  J Med Genet       Date:  1994-11       Impact factor: 6.318

9.  Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia.

Authors:  Tetsuya Suhara; Yoshiro Okubo; Fumihiko Yasuno; Yasuhiko Sudo; Makoto Inoue; Tetsuya Ichimiya; Yoshifumi Nakashima; Kazuhiko Nakayama; Shuji Tanada; Kazutoshi Suzuki; Christer Halldin; Lars Farde
Journal:  Arch Gen Psychiatry       Date:  2002-01

10.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

View more
  84 in total

Review 1.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

2.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

3.  Imaging of neuroinflammation.

Authors:  Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12       Impact factor: 9.236

Review 4.  In vivo imaging of neuroinflammation in schizophrenia.

Authors:  Ofer Pasternak; Marek Kubicki; Martha E Shenton
Journal:  Schizophr Res       Date:  2015-06-03       Impact factor: 4.939

Review 5.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

6.  Anti-neuroinflammatory effect of a novel caffeamide derivative, KS370G, in microglial cells.

Authors:  Dah-Yuu Lu; Bor-Ren Huang; Wei-Lan Yeh; Hsiao-Yun Lin; Shiang-Suo Huang; Yu-Shu Liu; Yueh-Hsiung Kuo
Journal:  Mol Neurobiol       Date:  2013-06-26       Impact factor: 5.590

Review 7.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

8.  Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.

Authors:  Andrea Crotti; Christopher Benner; Bilal E Kerman; David Gosselin; Clotilde Lagier-Tourenne; Chiara Zuccato; Elena Cattaneo; Fred H Gage; Don W Cleveland; Christopher K Glass
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

9.  Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.

Authors:  Paul B Larkin; Paul J Muchowski
Journal:  J Huntingtons Dis       Date:  2012

Review 10.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.